A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

Astellas Pharma Inc

Overview

A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Prostate Cancer Cancer of Prostate Prostatic Cancer Cancer of the Prostate

Interventions

YM155DRUG

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically or cytologically confirmed prostate cancer. * Prior chemotherapy regimen for prostate cancer Exclusion Criteria: * History of other malignancy in the last 5 years * Major surgery within the past 21 days

Locations (9)

Unnamed facility

Tuscon, Arizona, United States

Unnamed facility

Los Angeles, California, United States

Unnamed facility

Coeur d'Alene, Idaho, United States

Unnamed facility

New York, New York, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.